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Purpose: To describe a case of choroidal neovascularization (CNV) on the border of an inferior 
staphyloma associated with tilted disc syndrome treated with intravitreal ranibizumab.
Patients: Observational case report.
Methods: A patient with CNV on the border of an inferior staphyloma associated with tilted 
disc syndrome was imaged using fluorescein angiography, autofluorescence and spectral domain 
optical coherence tomography, and treated with intravitreal injections of ranibizumab.
Results: The patient received 3 ranibizumab injections during the 9-month follow-up. The 
visual acuity improved from 20/40 to 20/32 and the foveal thickness reduced from 470 microns 
to 248 microns. The angiograms showed resolution of leakage associated with CNV . There were 
no adverse events.
Conclusion: Intravitreal ranibizumab is an efficacious and safe treatment in the management 
of choroidal neovascularization on the border of an inferior staphyloma associated with tilted 
disc syndrome.
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Introduction
The main features that characterize eyes with tilted disc syndrome are oval optic disc with 
oblique axis, inferonasal crescent, situs inversus of the retinal vessels, myopic astigmatism 
and visual field defects.1–3 In addition, an inferior staphyloma is often associated with this 
syndrome and severe complications such as choroidal neovascularization (CNV) can occur 
when the border of the staphyloma lies across the macula.4–7 This CNV usually shows a 
classic pattern on fluorescein angiography (FA) resulting in significant visual loss.
Ranibizumab (Lucentis®; Genentech Inc, South San Francisco, California, USA) 
is a humanized antibody fragment designed to bind and inhibit all vascular endothelial 
growth factor-A (VEGF-A) isoforms. It was approved by the Food and Drug Admin-
istration (FDA) for the treatment of wet age-related macular degeneration in June 
2006. It has shown a great efficacy in the management of all angiographic subtypes 
of lesions in different clinical trials.8,9
We present a case of CNV on the border of an inferior staphyloma associated with 
tilted disc syndrome successfully treated with intravitreal ranibizumab.
Case report
A 77-year-old woman complained about visual acuity (VA) loss in her left eye in the 
previous 3 weeks. She had an uncomplicated cataract surgery in both eyes 4 years Clinical Ophthalmology 2010:4 228
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before. The patient did not have high myopia. The refractive 
error prior to cataract surgery was unknown since the patient 
was operated on in another hospital. However, the patient told 
us that she began to wear glasses when she was 45 years old. 
a) b)
c) d)
Figure 1 At baseline, the fundus photograph of the left eye revealed a tilted disc and the border of an inferior staphyloma lying across the macula and a subretinal lesion (a). 
Autofluorescence image showed mild hyperautofluorescence at the temporal border of the macula (b). Fluorescein angiography showed a well-defined predominantly classic 
choroidal neovascularization (CNV) in an early phase with leakage in a late phase (c, d). spectral domain optical coherence tomography scanning showed an irregular and 
elevated retinal pigment epithelium band with overlying CNV associated with intraretinal and subretinal fluid (e).
e)
At the moment of the examination her refractive error was 
90° −1.00 + 0.25 in her right eye and 90° −0.75 + 0.50 in 
her left eye. The axial length was 22.9 mm in the right eye 
and 23.2 mm in the left eye. Her VA measured with ETDRS Clinical Ophthalmology 2010:4 229
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(“Early Treatment of Diabetic Retinopathy Study”) charts 
was 20/20 in the right eye and 20/40 in the left eye. The ante-
rior segment examination showed transparent corneas and 
clear intraocular lenses located in the posterior chamber. The 
intraocular pressure was 16 mmHg in both eyes. The fundus 
examination revealed tilted discs and the border of an inferior 
staphyloma lying across the maculas in both eyes. Imaging 
with FA (Imagenet®; Topcon Corporation, Tokyo, Japan) 
showed an active predominantly classic CNV and a window 
defect on the border of the staphyloma. OCT scanning (OCT 
3-D, Topcon Corporation, Tokyo, Japan) showed an irregular 




Figure 2 After three intravitreal injections of ranibizumab, the fundus photograph of the left eye revealed a flat macula with pigmentary changes (a).   Autofluorescence image 
showed mild hyperautofluorescence at the temporal border of the macula (b). Fluorescein angiography showed staining but no leakage from the choroidal neovascular mem-
brane at the early phase and the late phase as well (c, d). Spectral domain optical coherence tomography scanning showed no intraretinal or subretinal fluid with restoration 
of the foveal contour (e).Clinical Ophthalmology 2010:4 230
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overlying CNV associated with intraretinal and subretinal 
fluid (Figure 1). The patient was informed about her disease 
and the risks and benefits of the treatment. An informed 
consent was obtained. We administered three monthly 
intravitreal injections of ranibizumab (0.5 mg/0.05 mL) 
in the office under sterile conditions. The VA before CNV 
development was not available. After the first injection, the 
VA improved from 20/40 to 20/32. No further improvement 
was observed after the second and the third injection. The 
angiograms showed resolution of leakage associated with 
CNV. OCT scanning showed no intraretinal or subretinal 
fluid with restoration of the foveal contour (Figure 2). The 
foveal thickness reduced from 470 microns to 248 microns. 
There were no adverse events. The VA and the angiograms 
and OCT findings remained unchanged during the 9-month 
follow-up with no further treatment.
Discussion
Severe visual loss has been reported on eyes with tilted disc 
syndrome when the upper-temporal border of an inferior 
staphyloma lies across the macula. It has been hypothesized 
that the sharp curve on the border of the staphyloma causes 
mechanical or hemodynamic changes and promotes the 
development of macular complications.2 Several published 
papers have described CNV in these cases.5–7 Recently, 
Nakanishi et al4 reviewed 32 eyes of 20 patients with tilted 
disc syndrome and inferior staphyloma lying across the 
macula. They found macular complications in 78% of the 
patients consisting of polypoidal choroidal vasculopathy 
(PCV) (22%), classic CNV (3%), focal serous retinal detach-
ment without PCV or CNV (41%) and atrophy of the RPE 
alone (13%). The VA of eyes with PCV or CNV was signifi-
cantly worse than in the other cases. However, they did not 
report the long-term evolution and visual outcome and the 
proposed treatment.
We decided to treat our patient with intravitreal 
ranibizumab with the recommended standard protocol 
of treatment.10 Ranibizumab is indicated for choroidal 
neovascular lesions with active disease with three initial 
consecutive monthly injections (loading dose) and thereafter 
monthly monitoring based on VA, fundus examination and 
OCT findings. This flexible strategy of treatment is effec-
tive and more feasible than continued monthly injections 
used in pivotal clinical trials.8,9 In our case, VA improved 
with resolution of angiographic leakage and OCT scanning 
edema. After the loading dose, our patient did not require 
any additional injection during the 9-month follow-up 
period. Nevertheless, it is likely that further treatment will 
be required with longer follow-up. We did not have any 
ocular or systemic side effect related to the drug or the route 
of administration.
The VA improved by one line, from 20/40 to 20/32. In 
comparison, a much more substantial anatomical benefit was 
observed, with resolution of the angiographic leakage and 
the intraretinal and subretinal fluid detected on OCT scans. 
However, it is known that visual gaining is often limited in 
predominantly classic lesions growing between the photo-
receptors and the RPE.
Photodynamic therapy with verteporfin could have 
been used as an alternative treatment in this patient. How-
ever, potential RPE damage could have limited visual 
recovery.11 Bevacizumab could have been used as an 
alternative treatment. However, it is not an approved drug for 
intraocular use in Spain. RPE rips have been reported with 
ranibizumab and bevacizumab as well. To our knowledge, no 
data support reduced risk of RPE rips with either ranibizumab 
or bevacizumab.
In summary, ranibizumab therapy can be used as an 
efficacious and safe treatment in the management of CNV 
associated with tilted disc syndrome. Nevertheless, this is 
only supported by a single case report. It would be desirable 
to accumulate more data to demonstrate potential safety and 
efficacy of ranibizumab in this condition.
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